Black Diamond Therapeutics Share Price Today
(NASDAQ: BDTX)

Name: Black Diamond Therapeutics Share Price Today (NASDAQ: BDTX) - Black Diamond Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Black Diamond Therapeutics share price is $2.44 & ₹212.52 as on 4 Feb 2025, 2.30 'hrs' IST

$2.44

▲

-0.18

(-6.87%)

Market is closed - opens 8 PM, 04 Feb 2025

View live Black Diamond Therapeutics share price in Dollar and Rupees. Guide to invest in Black Diamond Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Black Diamond Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Black Diamond Therapeutics share price movements

Today's Low: $2.35
Today's High: $2.54
$2.44
3.55%
Downside
Day's Volatility :7.16%
Upside
3.75%
52 Weeks Low: $1.91
52 Weeks High: $7.66
$2.44
21.72%
Downside
52 Weeks Volatility :75.07%
Upside
68.15%

Black Diamond Therapeutics (BDTX) Returns

Period	Black Diamond Therapeutics	Sector (Health Care)	Index (Russel 2000)
3 Months	-19.38%	-0.6%	0.0%
6 Months	-47.65%	-2.6%	0.0%
1 Year	-34.17%	3.4%	0.0%
3 Years	-34.66%	10.6%	-11.2%

Black Diamond Therapeutics (BDTX) Key Statistics

in dollars & INR

Previous Close	$2.62
Open	$2.51
Today's High	$2.535
Today's Low	$2.3535
Market Capitalization	$142.6M
Today's Volume	$979.0K
52 Week High	$7.66
52 Week Low	$1.91
Revenue TTM	$0.0
EBITDA	$-81.0M
Earnings Per Share (EPS)	$-1.33
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-63.09%

How to invest in Black Diamond Therapeutics Stock (BDTX) from India?

It is very easy for Indian residents to invest directly in Black Diamond Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Black Diamond Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Black Diamond Therapeutics or BDTX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Black Diamond Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Black Diamond Therapeutics shares which would translate to 0.357 fractional shares of Black Diamond Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Black Diamond Therapeutics, in just a few clicks!

Returns in Black Diamond Therapeutics (BDTX) for Indian investors in Rupees

The Black Diamond Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Black Diamond Therapeutics investment value today

Current value as on today

₹66,421

Returns

₹33,579

(-33.58%)

Returns from Black Diamond Therapeutics Stock

₹38,693 (-38.69%)

Dollar Returns

₹5,115 (+5.11%)

Indian investors sentiment towards Black Diamond Therapeutics (BDTX)

Period: Jan 4, 2025 to Feb 3, 2025. Change in 30 Days versus previous period

Search interest for Black Diamond Therapeutics Stock from India on INDmoney has increased by 3% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Black Diamond Therapeutics

T. Rowe Price Investment Management,Inc.
18.97%
Bellevue Group AG
15.05%
Vestal Point Capital LP
8.89%
NEA Management Company, LLC
7.86%
BlackRock Inc
6.18%
Vanguard Group Inc
4.10%

Analyst Recommendation on Black Diamond Therapeutics

Buy

91%Buy

8%Hold

0%Sell

Based on 12 Wall street analysts offering stock ratings for Black Diamond Therapeutics(by analysts ranked 0 to 5 stars)

Based on 12 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Black Diamond Therapeutics Stock (BDTX)

What analysts predicted

Upside of 494.26%

Target:

$14.50

Current:

$2.44

Insights on Black Diamond Therapeutics Stock (Ticker Symbol: BDTX)

Price Movement
In the last 7 days, BDTX stock has moved up by 6.9%
BDTX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 56.8% return, outperforming this stock by 97.1%
BDTX vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 90.4% return, outperforming this stock by 126.2%

Black Diamond Therapeutics Technicals Summary

Sell

Neutral

Buy

Black Diamond Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Black Diamond Therapeutics (BDTX) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Black Diamond Therapeutics	23.0%	-47.65%	-34.17%	-34.66%	-93.24%
Biontech Se	2.96%	55.69%	32.59%	-28.38%	275.86%
Regeneron Pharmaceuticals, Inc.	-6.04%	-36.88%	-28.13%	8.13%	72.63%
Vertex Pharmaceuticals Incorporated	14.71%	-2.66%	7.65%	89.79%	93.07%
Alnylam Pharmaceuticals, Inc.	16.37%	3.33%	58.94%	82.52%	122.46%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Black Diamond Therapeutics	NA	NA	NA	-1.27	-0.63	-0.33	NA	1.72
Biontech Se	160.8	NA	0.04	-3.32	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	16.89	16.89	1.06	44.96	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.15	0.49	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Black Diamond Therapeutics	Buy	$142.6M	-93.24%	NA	0.0%
Biontech Se	Buy	$29.0B	275.86%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.1B	72.63%	16.89	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$112.9B	93.07%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$35.7B	122.46%	NA	-15.86%

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Organization	Black Diamond Therapeutics
Employees	54
CEO	Dr. Mark A. Velleca M.D., Ph.D.
Industry	Health Technology

Management People of Black Diamond Therapeutics

Name	Title
Dr. Mark A. Velleca M.D., Ph.D.	CEO, President & Chairman
Dr. David M. Epstein Ph.D.	Co-Founder & Director
Dr. Sergey Yurasov M.D., Ph.D.	Chief Medical Officer
Dr. Elizabeth Buck Ph.D.	Co-Founder & Chief Scientific Officer
Ms. Erika Jones	Principal Financial Officer, Principal Accounting Officer, SVP of Finance & Corporate Controller
Mr. Brent Hatzis-Schoch Esq., J.D.	COO & General Counsel
Ms. Elizabeth L. Montgomery	Chief People Officer
Ms. Melanie Morrison	Chief Development Officer

Important FAQs about investing in BDTX Stock from India :

What is Black Diamond Therapeutics share price today?

Black Diamond Therapeutics share price today stands at $2.44, Open: $2.51 ; Previous Close: $2.62 ; High: $2.54 ; Low: $2.35 ; 52 Week High: $7.66 ; 52 Week Low: $1.91.

The stock opens at $2.51, after a previous close of $2.62. The stock reached a daily high of $2.54 and a low of $2.35, with a 52-week high of $7.66 and a 52-week low of $1.91.

Can Indians buy Black Diamond Therapeutics shares?

Yes, Indians can invest in the Black Diamond Therapeutics (BDTX) from India.

With INDmoney, you can buy Black Diamond Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Black Diamond Therapeutics at zero transaction cost.

How can I buy Black Diamond Therapeutics shares from India?

It is very easy to buy Black Diamond Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Black Diamond Therapeutics (BDTX) be purchased?

Yes, you can buy fractional shares of Black Diamond Therapeutics with INDmoney app.

What are the documents required to start investing in Black Diamond Therapeutics stocks?

To start investing in Black Diamond Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.